Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BRAIN Biotech AG's ROE % for the quarter that ended in Mar. 2026 was 0.00%. BRAIN Biotech AG's PB Ratio for the quarter that ended in Mar. 2026 was N/A.
BRAIN Biotech AG's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was N/A.
BRAIN Biotech AG ROE % Adjusted to Book Value Related Terms
BRAIN Biotech AG ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for BRAIN Biotech AG's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BRAIN Biotech AG ROE % Adjusted to Book Value Chart
LTS:0RFI vs LIN, SHW, ECL: ROE % Adjusted to Book Value Comparison
For the Specialty Chemicals subindustry, BRAIN Biotech AG's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BRAIN Biotech AG ROE % Adjusted to Book Value vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, BRAIN Biotech AG's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where BRAIN Biotech AG's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of 0.00% mean?
BRAIN Biotech AG (LTS:0RFI) has a ROE % Adjusted to Book Value of 0.00% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on BRAIN Biotech AG and its competitors.
Is BRAIN Biotech AG's ROE % Adjusted to Book Value too high?
BRAIN Biotech AG's current ROE % Adjusted to Book Value is 0.00%. Overall, BRAIN Biotech AG has a GF Score™ of 60/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BRAIN Biotech AG's ROE % Adjusted to Book Value compare to LIN and SHW?
BRAIN Biotech AG's ROE % Adjusted to Book Value of 0.00% can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Chemicals company?
A good ROE % Adjusted to Book Value depends on the Chemicals industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on BRAIN Biotech AG and its competitors. BRAIN Biotech AG's current ROE % Adjusted to Book Value is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BRAIN Biotech AG stock overvalued right now?
Based on GuruFocus' analysis, BRAIN Biotech AG (LTS:0RFI) is currently considered Fairly Valued. The stock's GF Value™ is €2.70, compared to a current price of €2.91 — trading 7.8% above its estimated fair value. The current ROE % Adjusted to Book Value is 0.00%. BRAIN Biotech AG's overall GF Score™ is 60/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For BRAIN Biotech AG (LTS:0RFI), the current ROE % Adjusted to Book Value is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BRAIN Biotech AG (LTS:0RFI) Overvalued in 2026?
Based on GuruFocus' analysis, BRAIN Biotech AG stock appears to be overvalued.
The current stock price of €2.91 is trading 7.8% above its estimated GF Value™ of €2.70.
GuruFocus considers BRAIN Biotech AG to be Fairly Valued.
Key valuation signals for LTS:0RFI:
ROE % Adjusted to Book Value: 0.00%
GF Value™: €2.70 vs. price of €2.91 (7.8% above fair value)
No single metric tells the full story. See the LTS:0RFI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BRAIN Biotech AG is an industrial biotechnology specialist focused on enzyme technology, microbial production strains, and bioprocess design to enable bio-based innovations. The Group conducts research, development, and production for client specifications and its own product portfolio, supporting customers in the food and beverage, chemical, and life sciences industries with solutions that enhance productivity, efficiency, and sustainability. Its operations are organized into two segments: BRAIN Biocatalysts, which develops, produces, and distributes specialty enzymes, microorganisms, and ingredients and generates the majority of revenue, and BRAIN BioIncubator, which focuses on development projects. The company operates in Germany and other countries.
60GF Score
Get the complete analysis for LTS:0RFI
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RFI has been successfully added to your 
